Login to Your Account



Search

Search results

Clinic roundup

Adamas Pharmaceuticals Inc., of Emeryville, Calif., reported the 340-mg dose of ADS-5102 resulted in a statistically significant improvement in overall Parkinson's disease clinical status, including levodopa-induced dyskinesia, when compared with pl ...

BioWorld Today - Staff - 2014-05-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceutical Industries Ltd ., of Jerusalem, reported positive results from a pivotal phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties ...

BioWorld Today - Staff - 2014-05-01 00:00 - 0 comments - 0 attachments

Clinic Roundup

No Abstract (BioWorld Today, BioWorld-Today-2009-11-04) ...

BioWorld Today - Staff - 2009-11-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Upsher-Smith Laboratories Inc. , of Maple Grove, Minn., reported phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66th Annual American Academy of Neurology (AAN) meeting in Philadelphia. ...

BioWorld Today - Staff - 2014-04-30 00:00 - 0 comments - 0 attachments

Clinic roundup

Biogen Idec Inc. , of Cambridge, Mass., announced two-year phase III data from the ADVANCE trial for Plegridy (peginterferon beta-1a) in relapsing multiple sclerosis (MS) patients. The data, which were presented at the 66th American Academy of Neurol ...

BioWorld Today - Staff - 2014-04-30 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Sanofi Pasteur, the vaccines division of Sanofi SA , of Paris, said the first of two pivotal phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint. The study showed a reduction of 56 percent of dengue ...

BioWorld Today - Staff - 2014-04-29 00:00 - 0 comments - 0 attachments

Clinic roundup

Xeris Pharmaceuticals Inc. , of Austin, Texas, said it dosed the first subject in a phase II study of its stable liquid glucagon in an Insulet Corp. (BioWorld-Today-2014-04-28) ...

BioWorld Today - Staff - 2014-04-28 00:00 - 0 comments - 0 attachments

Clinic roundup

Vernalis plc , of Winnersh, U.K., reported the results from a phase Ib/II proof-of-concept study of V81444, an A2A antagonist which has potential applications for the treatment of Parkinson's disease, attention deficit hyperactivity disorder (ADHD) a ...

BioWorld Today - Staff - 2014-04-25 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceutical Industries Ltd. , of Jerusalem, said it enrolled the first patient in the Pride-HD study, a phase II trial designed to evaluate the impact of pridopidine, an oral, small molecule, on motor impairment in patients with Huntington's ...

BioWorld Today - Staff - 2014-04-25 00:00 - 0 comments - 0 attachments

Clinic roundup

Alder Biopharmaceuticals Inc. , of Bothell, Wash., said researchers will present findings from a randomized, double-blind, placebo-controlled proof-of-concept trial of lead compound ALD403 in preventing frequent episodic migraine at the American Acad ...

BioWorld Today - Staff - 2014-04-24 00:00 - 0 comments - 0 attachments